Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura

Haematologica

Volumn 89, Issue 3, 2004, Pages 320-324

  Kremer Hovinga, Johanna A ^a   Studt, Jan Dirk ^a   Biasiutti, Franziska Demarmels ^a   Solenthaler, Max ^a   Alberio, Lorenzo ^a   Zwicky, Caroline ^a   Fontana, Stefano ^a   Taleghani, Behrouz Mansouri ^a   Tobler, Andreas ^a   Lämmle, Bernhard ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

ADAMTS 13 activity; Autoantibody; Relapse; Splenectomy; Thrombotic thrombocytopenic purpura

Indexed keywords

AUTOANTIBODY; FRESH FROZEN PLASMA; IMMUNOSUPPRESSIVE AGENT; VINCRISTINE; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; CASE REPORT; CONVALESCENCE; DISEASE COURSE; ENZYME ACTIVITY; FATALITY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PLASMAPHERESIS; RELAPSE; SPLENECTOMY; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT INDICATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METALLOENDOPEPTIDASES; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; SPLENECTOMY;

EID: 2942744303     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Torok TJ, Holman RC, Chorba TL. Increasing mortality from thrombotic thrombocytopenic purpura in the United States-analysis of national mortality data, 1968-1991. Am J Hematol 1995;50:84-90.
2. Rock GA. Management of thrombotic thrombocytopenic purpura. Br J Haematol 2000;109:496-507.
3. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002;347:589-600.
4. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-84.
5. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-94.
6. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001;98:1662-6.
7. Gerritsen HE, Robles R, Lämmle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 2001;98:1654-61.
8. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001;276:41059-63.
9. Soejima K, Mimura N, Hirashima M, Maeda H, Hamamoto T, Nakagaki T, et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J Biochem (Tokyo) 2001;130:475-80.
10. Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982;307:1432-5.
11. Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol 2001;14:437-54.
12. Allford SL, Harrison P, Lawrie AS, Liesner R, MacKie IJ, Machin SJ. Von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura. Br J Haematol 2000;111:1215-22.
13. Furlan M, Robles R, Solenthaler M, Lämmle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998;91:2839-46.
14. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001;413:488-94.
15. Kokame K, Matsumoto M, Soejima K, Yagi H, Ishizashi H, Funato M, et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A 2002;99:11902-7.
16. Schneppenheim R, Budde U, Oyen F, Angerhaus D, Aumann V, Drewke E, et al. Von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP. Blood 2003;101:1845-50.
17. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991;325:393-7.
18. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991;325:398-403.
19. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000;96:1223-9.
20. Shumak KH, Rock GA, Nair RC. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Ann Intern Med 1995;122:569-72.
21. Kappers-Klunne MC, van der Meulen JH, Holdrinet RS, van der Meer J, Wijermans PW, Brand A. Thrombotic thrombocytopenic purpura in 13 Dutch centres: treatment and longterm follow-up. Ned Tijdschr Geneeskd 1997;141:1192-6.
22. Vesely SK, George JN, Lämmle B, Studt JD, Alberio L, El-Harake MA, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003;102:60-68.
23. Bianchi V, Robles R, Alberio L, Furlan M, Lämmle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002;100:710-3.
24. Gutterman LA, Kloster B, Tsai HM. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis 2002;28:385-91.
25. Chemnitz J, Draube A, Scheid C, Staib P, Schulz A, Diehl V, et al. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol 2002;71:105-8.
26. Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med 2003;138:105-8.
27. Tsai HM, Shulman K. Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura. Eur J Haematol 2003;70:183-5.
28. Cuttner J. Thrombotic thrombocytopenic purpura: a ten-year experience. Blood 1980;56:302-6.
29. Schneider PA, Rayner AA, Linker CA, Schuman MA, Liu ET, Hohn DC. The role of splenectomy in multimodality treatment of thrombotic thrombocytopenic purpura. Ann Surg 1985;202:318-22.
30. Onundarson PT, Rowe JM, Heal JM, Francis CW. Response to plasma exchange and splenectomy in thrombotic thrombocytopenic purpura. A 10-year experience at a single institution. Arch Intern Med 1992;152:791-6.
31. Veltman GA, Brand A, Leeksma OC, ten Bosch GJ, van Krieken JH, Briet E. The role of splenectomy in the treatment of relapsing thrombotic thrombocytopenic purpura. Ann Hematol 1995;70:231-6.
32. Crowther MA, Heddle N, Hayward CP, Warkentin T, Kelton JG. Splenectomy done during hematologic remission to prevent relapse in patients with thrombotic thrombocytopenic purpura. Ann Intern Med 1996;125:294-6.
33. Eldor A. Thrombotic thrombocytopenic purpura: diagnosis, pathogenesis and modern therapy. Baillière's Clin Haematol 1998;11:475-95.
34. Schwartz J, Eldor A, Szold A. Laparoscopic splenectomy in patients with refractory or relapsing thrombotic thrombocytopenic purpura. Arch Surg 2001;136:1236-8; discussion 1239.
35. Aqui NA, Stein SH, Konkle BA, Abrams CS, Strobl FJ. Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura. J Clin Apheresis 2003;18:51-4.